ICE Bioscience Posters

Download

Neuroinflammation is a vital immune response within the central nervous system (CNS), predominantly orchestrated by microglia and astrocytes. It is not merely a byproduct of neurodegeneration but also a pivotal catalyst in this process. These cells are the primary sources of inflammatory factors in neuroinflammation and are implicated in nearly all neurodegenerative diseases, including Alzheimer's and Parkinson's.

Several signaling pathways have been identified as being integral to the genesis of neuroinflammation. To advance our understanding and facilitate drug evaluation in this field, ICE has established a comprehensive neuroinflammation drug evaluation platform. This platform is designed to study the complex interplay of these pathways and to test potential therapeutics aimed at mitigating neuroinflammatory responses.

Download

Androgen Receptor (AR) belongs to the steroid receptor subfamily of the nuclear receptor superfamily. As a transcription factor, AR is responsible for regulating the physiological effects of androgens, such as testosterone and dihydrotestosterone (DHT), plays a pivotal role in the initiation and advancement of prostate cancer (PCa) and breast cancer (BC), with therapeutic approaches primarily focusing on the modulation of the AR signaling pathway.

We constructed an integrated experimental cascade, including biochemical and cell-based assays to conduct the high throughput hit-to-lead compound screening. Meanwhile, CDX modes are constructed for promisingly conducting in-vivo experiments and biomarker detection. Thus, ICE supports multiple approaches for helping the drug discovery and development of AR to facilitate the treatment of PCa and BC.

Download

The DNA damage response (DDR) encompasses a series of cellular processes that detect and repair genomic lesions. Targeting DDR pathways and inhibiting DNA repair mechanisms have emerged as promising strategies in cancer therapy, and significant progress has been made in the discovery of DDR-related inhibitors. However, drug resistance has become an increasingly prevalent challenge in this field. To better understand compound potency across various cancer cell lines, we generated drug-sensitive and drug-resistant cell lines by knocking out key DDR genes (e.g., BRCA1/2, XRCC1) and culturing cells under selective pressure from PARP inhibitors. Additionally, together with wild-type (WT) cells commonly used in DDR-related drug discovery, we established a DDR cell panel encompassing 14 distinct cancer types. This panel has been rigorously validated through in vitro proliferation assays and in vivo efficacy studies. Furthermore, sequencing and bioinformatic analyses have been employed to elucidate the mechanisms underlying drug sensitivity and resistance. Our findings demonstrate that this DDR cell panel offers a rapid and comprehensive platform for evaluating DDR inhibitors, thereby facilitating the efficient discovery of novel therapeutics in cancer treatment.

Download

Methyltransferase-like 3 (METTL3) is the only catalytic subunit of the transferase complex responsible for m6A modification, and it has been found to play a key role in tumorigenesis, tumor growth, metastasis and tumor drug resistance. In recent years, METTL3 has attracted more and more attention as a potential target for cancer treatment.

On this basis, we established an in vitro and in vivo screening platform on METTL3/14 complex, which can realize high-throughput screening of METTL3 inhibitors in vitro experiments. High purity METTL3/14 protein complex has been successfully purified and used in develop METTL3/14 biochemical experiments. We have also established different cellular assays, including proliferation and m6A RNA Methylation quantification assay. Lastly, CDX models utilizing different Ovarian cell lines have been validated. We aim to aid the discovery of new drugs through the METTL3/14 screening cascade.